Gossamer Bio Appoints New CEO, Dr. Gujrathi Takes Helm
Ticker: GOSS · Form: 8-K · Filed: 2024-03-12T00:00:00.000Z
Sentiment: neutral
Topics: leadership-change, management-transition, ceo-appointment
TL;DR
Gujrathi is the new CEO of Gossamer Bio, replacing Harris.
AI Summary
Gossamer Bio, Inc. announced on March 11, 2024, the appointment of Dr. Sheila Gujrathi as Chief Executive Officer and a member of the Board of Directors, effective immediately. Dr. Gujrathi, previously the Chief Medical Officer, will also serve as President. The company also announced the departure of F. Scott Harris as CEO and from the Board. Additionally, the company entered into a new employment agreement with Dr. Gujrathi.
Why It Matters
This leadership change signifies a strategic shift for Gossamer Bio, with the new CEO likely to drive the company's future direction and pipeline development.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding strategic direction and operational execution.
Key Players & Entities
- Gossamer Bio, Inc. (company) — The company filing the report.
- Dr. Sheila Gujrathi (person) — Appointed as CEO and Board member.
- F. Scott Harris (person) — Departed as CEO and from the Board.
- March 11, 2024 (date) — Effective date of the leadership changes.
FAQ
Who has been appointed as the new CEO of Gossamer Bio?
Dr. Sheila Gujrathi has been appointed as the new Chief Executive Officer of Gossamer Bio.
When did the leadership changes become effective?
The leadership changes became effective on March 11, 2024.
Who was the previous CEO of Gossamer Bio?
F. Scott Harris was the previous CEO of Gossamer Bio.
What other roles will Dr. Gujrathi assume?
Dr. Gujrathi will also serve as President and a member of the Board of Directors.
What is the company's principal executive office address?
The principal executive offices are located at 3013 Science Park Road, San Diego, California, 92121.
Filing Stats: 870 words · 3 min read · ~3 pages · Grade level 9.6 · Accepted 2024-03-12 16:01:17
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share GOSS Nasdaq Global
- $1 billion — l Head of Healthcare managing more than $1 billion in assets for Credit Suisse Asset Manag
- $40,000 — will receive an annual cash retainer of $40,000 for service on the Board and (ii) was g
Filing Documents
- goss-20240311.htm (8-K) — 34KB
- goss-20240312xxex991xnewdi.htm (EX-99.1) — 10KB
- image_0.jpg (GRAPHIC) — 17KB
- 0001728117-24-000024.txt ( ) — 192KB
- goss-20240311.xsd (EX-101.SCH) — 2KB
- goss-20240311_lab.xml (EX-101.LAB) — 21KB
- goss-20240311_pre.xml (EX-101.PRE) — 12KB
- goss-20240311_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No Description 99.1 Press Release dated March 12 , 202 4 . 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. GOSSAMER BIO, INC. Date: March 12, 2024 By: /s/ Christian Waage Christian Waage Executive Vice President, Technical Operations & Administration 3